Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Down 43.6% in April

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totalling 18,500 shares, a decline of 43.6% from the March 31st total of 32,800 shares. Currently, 1.1% of the shares of the company are sold short. Based on an average trading volume of 391,900 shares, the short-interest ratio is presently 0.0 days.

Revelation Biosciences Trading Up 1.9 %

Shares of Revelation Biosciences stock traded up $0.04 on Friday, reaching $2.18. 45,620 shares of the stock were exchanged, compared to its average volume of 315,485. The firm has a market capitalization of $3.55 million, a PE ratio of 0.07 and a beta of 0.11. Revelation Biosciences has a 1-year low of $1.78 and a 1-year high of $39.00. The business has a fifty day moving average price of $2.68 and a two-hundred day moving average price of $10.90.

Revelation Biosciences (NASDAQ:REVB) last released its earnings results on Friday, March 22nd. The company reported ($8.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($10.94) by $2.61. Research analysts expect that Revelation Biosciences will post -20.32 EPS for the current year.

Institutional Investors Weigh In On Revelation Biosciences

A hedge fund recently raised its stake in Revelation Biosciences stock. Sabby Management LLC increased its stake in Revelation Biosciences, Inc. (NASDAQ:REVB) by 14.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 403,233 shares of the company’s stock after purchasing an additional 50,000 shares during the quarter. Revelation Biosciences accounts for 0.2% of Sabby Management LLC’s investment portfolio, making the stock its 20th largest position. Sabby Management LLC owned approximately 6.40% of Revelation Biosciences worth $278,000 as of its most recent filing with the Securities & Exchange Commission. 12.80% of the stock is owned by institutional investors and hedge funds.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease.